PDCD1 and non-small cell lung carcinoma: Subsequent human studies with CTLA-4 and programed cell death-1 (PD-1) blockade have shown improved overall survival in patients with metastatic melanoma, as well as non-small cell lung cancer, breast, and renal cell carcinoma [18,19,20,21].